HPLC is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-12-31. Numbers and descriptions here follow the published literature rather than marketing material.
Stability of NAD+ depends on form, temperature, pH, and water content. The solid is generally more stable than solutions, and it should be kept dry and cold. In solution, hydrolysis can cleave the dinucleotide, especially under alkaline conditions or at elevated temperature. Light exposure may also contribute to degradation. Buffers, chelating agents, and sterile handling can reduce losses, but no single condition preserves all preparations indefinitely. Researchers often prepare working solutions shortly before use and verify activity or purity after storage.
Quality control for NAD+ relies on identity, purity, and functional tests. A certificate of analysis may report high-performance liquid chromatography purity, ultraviolet spectrum, water content, and residual solvents. Because NAD+ is hygroscopic, gravimetric values can shift as material absorbs water, so purity should be interpreted alongside storage history. Mass spectrometry confirms molecular identity, while enzymatic assays show whether the material supports dehydrogenase activity. Commercial material is available as the free acid and as salts, and the counterion affects molecular weight, solubility, and how concentrations are calculated.
NAD+ is commonly measured by high-performance liquid chromatography with ultraviolet detection, often at 254 or 260 nm. Enzymatic cycling assays provide higher sensitivity by coupling NAD+ to a reporter reaction. Mass spectrometry can distinguish NAD+ from close analogues and confirm isotope labeling. Sample preparation usually involves rapid quenching of metabolism to prevent interconversion with NADH. Because NAD+ and NADH differ by one hydride, extraction conditions strongly affect the measured ratio.
In aqueous solution, NAD+ is most stable under mildly acidic to neutral conditions and degrades faster at high pH or elevated temperature. The molecule can hydrolyze at the pyrophosphate bond or undergo nonenzymatic cyclization. Buffers, chelating agents, and cold temperatures slow these losses during analysis. Repeated freeze-thaw cycles are generally avoided because they can promote degradation and concentration changes. Light exposure is also controlled, though NAD+ is less photolabile than some related nucleotides.
| Property | Value | Notes |
|---|---|---|
| CAS number | 53-84-9 | Refers to the free acid form of NAD+. |
| Molecular formula | C21H27N7O14P2 | Free acid; salts include additional counterions. |
| UV absorbance maximum | 259-260 nm | Used for detection and concentration estimation. |
| Typical storage | -20 °C or below, desiccated | Protect from light and moisture; avoid repeated freeze-thaw. |
| Common analytical method | HPLC-UV or LC-MS | Enzymatic cycling is an alternative for low-abundance samples. |
Beyond redox catalysis, NAD+ is a substrate for enzymes that transfer ADP-ribose or remove acetyl groups from proteins. Sirtuins and poly(ADP-ribose) polymerases consume NAD+ and release nicotinamide as a byproduct. These reactions connect cellular energy status to gene regulation, DNA repair, and stress responses. Because NAD+ is used rather than merely recycled in such signaling, its concentration reflects both biosynthesis and consumption. The balance between salvage and de novo synthesis pathways determines available pools in different tissues.
Biosynthesis of NAD+ starts from nicotinamide, nicotinic acid, or nicotinamide riboside through salvage pathways. A rate-limiting enzyme, nicotinamide phosphoribosyltransferase, converts nicotinamide to nicotinamide mononucleotide. Further coupling with ATP yields NAD+. In mammals, the liver and muscle can synthesize NAD+ from dietary precursors, but tissue levels vary widely. Researchers study these pathways to understand age-related changes, metabolic disorders, and neurodegeneration. Direct causal links between NAD+ decline and disease remain an active area of investigation.
NAD+ is a dinucleotide composed of adenine, ribose, and nicotinamide groups joined by phosphate linkages. It serves as a coenzyme in oxidoreductase reactions, cycling between oxidized NAD+ and reduced NADH. The molecule is water-soluble and occurs in all living cells. Its nicotinamide ring accepts hydride ions during catabolic reactions, linking substrate oxidation to electron transport. This redox couple supports ATP production and helps maintain cytosolic and mitochondrial redox balance in many cell types.
Beyond electron transfer, NAD+ serves as a substrate for enzymes that cleave the molecule and transfer ADP-ribose units. Sirtuins, poly(ADP-ribose) polymerases, and CD38 consume NAD+ in regulatory reactions. These activities link NAD+ availability to DNA repair, chromatin modification, calcium signaling, and metabolic stress responses. Because consumption can exceed biosynthesis under some conditions, cellular NAD+ levels are dynamic rather than fixed. Enzyme affinity and local synthesis also influence how much NAD+ is available for signaling.
NAD+ is a dinucleotide composed of adenine, ribose, and nicotinamide moieties linked by phosphate groups. Its oxidized form carries a positive charge on the nicotinamide ring, which enables reversible hydride transfer. The molecule functions as a coenzyme in oxidoreductase reactions rather than as a dietary vitamin in its intact form. Cells maintain separate pools in cytoplasm, mitochondria, and nucleus. This compartmentalization allows distinct redox environments while preserving a shared chemical identity.
In glycolysis, NAD+ accepts electrons during the oxidation of glyceraldehyde-3-phosphate, forming NADH. The tricarboxylic acid cycle and fatty acid oxidation also generate NADH, which donates electrons to the mitochondrial electron transport chain. This flow supports ATP synthesis and helps maintain the redox balance of the cell. Other dehydrogenases use NAD+ as a cofactor for biosynthetic reductions and detoxification reactions. NADH is later reoxidized to sustain continued flux through these pathways.
Cells produce NAD+ through several biosynthetic routes. The salvage pathway recycles nicotinamide, while the Preiss-Handler pathway uses nicotinic acid, and a de novo route can start from tryptophan in some organisms. In mammals, the salvage pathway is generally considered the main source under ordinary conditions. Tissue concentrations vary widely by cell type and compartment, and measured declines with age have been reported in some studies. Whether such changes drive aging or mainly accompany it remains an open question.
Nicotinamide adenine dinucleotide, commonly abbreviated NAD+, is a coenzyme present in all living cells. The molecule consists of two nucleotides linked by phosphate groups, with adenine and a nicotinamide ring as its principal features. In its oxidized form, the nicotinamide ring can accept a hydride ion, becoming NADH. This reversible conversion places NAD+ at the center of many electron-transfer reactions. Its role as a redox carrier is well established across bacteria, plants, fungi, and animals.
=== Distribution === Met-enkephalin is found mainly in the adrenal medulla and throughout the central nervous system (CNS), including in the striatum, cerebral cortex, olfactory tubercle, hippocampus, septum, thalamus, and periaqueductal gray, as well as the dorsal horn of the spinal cord. It is also present in the periphery, notably in some primary afferent fibers that innervate the pelvic viscera.
=== Media === In France, the French syndicate of non-alcoholic beverages "Boissons Rafraîchissantes de France" (that included soft drink producers such as Coca-Cola France, Orangina, PepsiCo France) was denounced by the French journal fr:Canard Enchainé for misleading consumers using a communication on their website titled "Better understanding the NASH pathology", explaining that "NASH pathology is sometimes called the soda illness by language abuse or an unfortunate semantic shortcut, as it is not directly linked to the consumption of non-alcoholic beverages". This page and others on the same website, such as one titled "Say no to disinformation," were removed since then.
=== RNA interference === RNA interference (RNAi) uses segments of RNA to fatally silence crucial insect genes. In 2024 two uses of RNAi have been registered by the authorities for use: Genetic modification of a crop to introduce a gene coding for an RNAi fragment and spraying double stranded RNA fragments onto a field. Monsanto introduced the trait DvSnf7 which expresses a double-stranded RNA transcript containing a 240 bp fragment of the WCR Snf7 gene of the Western Corn Rootworm. GreenLight Biosciences introduced Ledprona, a formulation of double stranded RNA as a spray for potato fields. It targets the essential gene for proteasome subunit beta type-5 (PSMB5) in the Colorado potato beetle.
Sources: en.wikipedia.org
=== Economic impact === In addition to its health impacts, obesity can lead to many problems, including disadvantages in employment and increased business costs. Research estimated the medical costs attributable to obesity in the US in 2005 at $190.2 billion or 20.6% of all medical expenditures, while the cost of obesity in Canada was estimated at CA$2 billion in 1997 (2.4% of total health costs). The total annual direct cost of overweight and obesity in Australia in 2005 was A$21 billion. Overweight and obese Australians also received A$35.6 billion in government subsidies. The estimated range for annual expenditures on diet products is $40 billion to $100 billion in the US alone. The Lancet Commission on Obesity in 2019 called for a global treaty—modelled on the WHO Framework Convention on Tobacco Control—committing countries to address obesity and undernutrition, explicitly excluding the food industry from policy development. They estimated the global cost of obesity at $2 trillion a year, about or 2.8% of world GDP. Obesity-prevention programs demonstrably reduce the cost of treating obesity-related disease. However, the longer people live, the more medical costs they incur. Analysis therefore concludes that reducing obesity may improve the public's health, but that it is unlikely to reduce health spending overall. Globally, certain countries have implemented sin taxes (such as a sugary drink tax) to curb dietary and consumer habits and to offset economic costs.
On 1 May 1999 Pudzianowski entered his first Strongman competition, held in Płock, Poland. He achieved his first major success at the international level at the 2000 World's Strongest Man contest where he finished fourth in his first WSM competition. Due to his prison sentence, he did not return for the 2001 competition. Pudzianowski returned at the 2002 World's Strongest Man and won his first title. He retained his title at the 2003 World's Strongest Man with an event to spare, winning by the largest margin ever achieved in the competition; across the seven disciplines in the final, he scored a remarkable four first place finishes, two second place finishes and one third place finish, resulting in the points margin between first and second (20) being greater than the margin between second and ninth (18). British strongman Laurence Shahlaei has since called this performance the most dominant victory ever seen at a World's Strongest Man event. In March 2004, he also became the Strongman Super Series World Champion. He initially finished third in the 2004 World's Strongest Man but was later disqualified for breaching the governing body's Strongman Health Policy. He was forced to return his prize money, stripped of the International Federation of Strength Athletes points from the event, and received a one-year ban from competition. Pudzianowski did not dispute his banned substance violation and waived his right to have his stool sample verified. In 2005, he made his return to World's Strongest Man event.
== Causes == Myxedema is known to occur in various forms of hypothyroidism, as well as hyperthyroidism, including Graves' disease. One of the hallmarks of Graves' disease is pretibial myxedema, myxedema of the lower limb. Myxedema is more common in women than in men. Myxedema can occur in:
Note that these constants are dissociation constants because the products on the right hand side of the equilibrium expression are dissociation products. In many systems, it is preferable to use association constants.
Sources: en.wikipedia.org
Common methods include enzymatic cycling assays, HPLC with UV detection, and LC-MS. The choice depends on sample size, specificity needs, and available equipment. Rapid quenching before analysis is important because NAD+ and NADH can interconvert.
Water promotes hydrolysis, and heat accelerates degradation. Cold, dry storage slows these processes. Repeated warming and cooling can introduce moisture and condensation, so aliquoting is often used.
Yes. They may be free acid or salts, with different counterions and purity grades. The counterion changes molecular weight, so concentration calculations should account for the actual form. Certificates of analysis provide batch-specific information.
NAD+ and NADH can interconvert quickly after a sample is collected, which can alter the measured ratio. Rapid quenching and cold handling limit enzymatic and chemical changes.